Narrative review highlights cancer immunotherapy advances via immune checkpoint inhibitors and vaccines, indicating combined therapies may enhance effectiveness in resistant cancers.
Key Points
Immunotherapy shows improved anti-tumor immunity in various cancer types, particularly with immune checkpoint inhibitors.
Promising results in non-small-cell lung cancer and melanoma suggest a shift in cancer treatment paradigms.
Observational analysis of clinical trials emphasizes diverse therapeutic approaches for overcoming resistance mechanisms.
Continued innovation in cancer vaccines may broaden applications and boost response rates against solid tumors.